Skip to main navigation

Contact Us

Investor Relations

Our Company
Product Candidates
- Pipeline
- MultiTAA Therapies
Our Science
Clinical Trials
- Active Clinical Trials
- Expanded Access Policy
Investors/Media
Careers

Investors/Media

Press Releases

Press Releases

Year

May 04, 2020

Marker Therapeutics to Host First Quarter 2020 Operating and Financial Results Conference Call and Webcast on Monday, May 11, 2020

Apr 29, 2020

Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia

Mar 12, 2020

Marker Therapeutics Reports Full Year 2019 Operating and Financial Results

Mar 02, 2020

Marker Therapeutics and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $30 million

Feb 18, 2020

Marker Therapeutics to Present at Two Upcoming Investor Conferences

Feb 11, 2020

Marker Therapeutics Announces Update to its Clinical Program in AML

Nov 25, 2019

Marker Therapeutics to Present at Two Upcoming Investor Conferences

Nov 12, 2019

Marker Therapeutics Reports Third Quarter 2019 Operating and Financial Results

Nov 11, 2019

Marker Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast on Tuesday, November 12, 2019

Aug 15, 2019

Marker Therapeutics Appoints Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs

Pagination

First page
Previous page
…
Page 5
Page 6
Page 7
Page 8
Page 9
Current page 10
Page 11
Page 12
Page 13
Next page
Last page

Displaying 91 - 100 of 126

Investors/Media

Investors/Media Home
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials & Filings
Corporate Governance
Investor Resources

IR and Media Contacts

investor.relations@markertherapeutics.com
(713) 400-6400

©2026 Marker Therapeutics, Inc. All Rights Reserved.

Footer Links

Sitemap
Terms of Use
Privacy Policy